{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:34:22Z","timestamp":1790087662018,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022336","name":"Esperion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jacl.2022.03.001","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T10:34:05Z","timestamp":1647167645000},"page":"286-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-9323","authenticated-orcid":false,"given":"Ulrich","family":"Laufs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9912-1408","authenticated-orcid":false,"given":"Harold","family":"Bays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-2094","authenticated-orcid":false,"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-5154","authenticated-orcid":false,"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne C.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio M.","family":"Gotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeAnne T.","family":"Bloedon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. B. John","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2022.03.001_bib0001","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2022.03.001_bib0002","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2022.03.001_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.jacl.2022.03.001_bib0004","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0005","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jval.2016.03.1858","article-title":"Development and validation of algorithms to identify statin intolerance in a US administrative database","volume":"19","author":"Schulman","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jacl.2022.03.001_bib0006","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2022.03.001_bib0007","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13219","article-title":"Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study","volume":"290","author":"Casula","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2022.03.001_bib0008","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0009","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/M16-0838","article-title":"Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study","volume":"167","author":"Zhang","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2022.03.001_bib0010","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0011","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing cholesterol treatment in patients with muscle complaints","volume":"70","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0012","first-page":"225","article-title":"Statin Intolerance: some practical hints","volume":"36","author":"Banach","year":"2018","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jacl.2022.03.001_bib0013","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"The National Lipid Association\u2019s muscle safety expert panel. An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0014","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2022.03.001_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2018.02.085","article-title":"Does Googling lead to statin intolerance?","volume":"262","author":"Khan","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0016","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1093\/eurheartj\/ehab358","article-title":"Nocebo\/drucebo effect in statin-intolerant patients: an attempt at recommendations","volume":"42","author":"Penson","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2022.03.001_bib0017","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacl.2022.03.001_bib0018","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2022.03.001_bib0019","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2022.03.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2022.03.001_bib0021","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.03.001_bib0022","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.03.001_bib0023","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","article-title":"Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance","volume":"235","author":"Nicholls","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2022.03.001_bib0024","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0025","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0026","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2022.03.001_bib0027","article-title":"Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin\/ezetimibe compared to separate pill combination on LDL-C","author":"Katzmann","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0028","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2022.03.001_bib0029","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2022.03.001_bib0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.amjcard.2008.09.090","article-title":"Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy","volume":"103","author":"Pearson","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0031","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.amjcard.2003.08.048","article-title":"Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein","volume":"92","author":"Sager","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0032","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2022.03.001_bib0033","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2022.03.001_bib0034","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","author":"Russo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2022.03.001_bib0035","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/07853890.2021.1956686","article-title":"Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants","volume":"53","author":"Vahedian-Azimi","year":"2021","journal-title":"Ann Med"},{"key":"10.1016\/j.jacl.2022.03.001_bib0036","series-title":"Prescribing Information","year":"2020"},{"key":"10.1016\/j.jacl.2022.03.001_bib0037","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1742-1241.2003.tb10508.x","article-title":"Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies","volume":"57","author":"Knopp","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2022.03.001_bib0038","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMp1112023","article-title":"Needed: pragmatic clinical trials for statin-intolerant patients","volume":"365","author":"Maningat","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.03.001_bib0039","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/2047487315602861","article-title":"Statin tolerability: in defence of placebo-controlled trials","volume":"23","author":"Tobert","year":"2016","journal-title":"Eur J Prev Cardiol"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:37:22Z","timestamp":1761831442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287422000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1933287422000344"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2022.03.001","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2022.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}